John R Wunderlich

Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy

S. Rosenberg, P. Robbins, M. Dudley, 2008, Journal of immunotherapy.

Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.

S. Rosenberg, M. Dudley, J. Wunderlich, 2009, Journal of immunological methods.

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Sadik H. Kassim, M. Raffeld, S. Rosenberg, 2014, Clinical Cancer Research.

Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

Seth M Steinberg, S. Steinberg, S. Rosenberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

S. Rosenberg, Alexandria P. Cogdill, R. Morgan, 2009, Blood.

Intralymphatic Dendritic Cell Vaccination Induces Tumor Antigen–Specific, Skin-Homing T Lymphocytes

Gang Wang, Gregory Lizée, G. Wang, 2006, Clinical Cancer Research.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

M. Raffeld, S. Rosenberg, R. Morgan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.